BibTex RIS Kaynak Göster

Pregabalin ilişkili döküntü: Olgu sunumu

Yıl 2013, , 107 - 109, 01.03.2013
https://doi.org/10.5799/ahinjs.01.2013.01.0244

Öz

Kırksekiz yaşında ve 2 aydır nöropati tedavisi için 300 mg/gün oral yolla pregabalin kullanan erkek hasta, eks­tremiteler ve lomber bölgesinde eritematöz, makülopapü­ler döküntü şikayeti ile başvurdu. Naranjo olasılık skalası döküntü ve pregabalin kullanımı arasında muhtemel bir ilişkiyi gösterdi. Pregabalin tedavisi kesilerek, antihistami­nik tedavi, oral metilprednizolon ve topical steroidli krem başlandı. Tedavinin kesilmesinden 1 hafta sonra döküntü neredeyse tamamen düzeldi. Pregabalin ilişkili döküntü faz 3 klinik çalışmalarda nadiren rapor edilmiştir. Prega­balin kullanımına eşlik eden döküntü daha önce yalnızca bir vaka raporunda sunulmuştur. Pregabalin ilişkili dökün­tünün mekanizması tam olarak anlaşılamamıştır. Düşük dozlarda pregabalin tedavisine başlamak ve doz artımını yavaş yapmak yan etki insidansını azaltabilir.

Kaynakça

  • Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105:1805- 1815.
  • Mula M, Pini S, Cassano GB. The role of anticonvul- sant drugs in anxiety disorders: a critical review of the evi-dence. J Clin Psychopharmacol 2007;27:263-272.
  • Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008;1:561-562.
  • Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-1709.
  • Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapen- tin, lamotrigine, and carbamazepine. Neurology 2005;64:1868-1873.
  • Smith TL, Baldwin A, Cunningham LL Jr, et al. Rash Associated with Pregabalin Use. Ann Pharmacother 2008;42:1899-1902.
  • Pushkin R, Frassetto L, Tsourounis C, et al. Improving the reporting of adverse drug reactions in the hospital set-ting. Postgrad Med 2010;122:154-164.
  • Alvestad S, Lydersen S, Brodtkorb E. Rash from anti- epileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007;48:1360-1365.
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
  • Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug- induced skin, nail and hair disorders. Drug Saf 2007;30:1011-1030.
  • Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with prega- balin: A randomized, placebo-controlled trial. J Pain 2005;6:253-260.
  • Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;63:2104- 2110.
  • Rosenstock J, Tuchman M, LaMoreaux L, et al. Pre- gabalin for the treatment of painful diabetic peripheral neuropathy: A double blind, placebo-controlled trial. Pain 2004;110:628-638.
  • Arezzo JC, Rosenstock J, Lamoreaux L, et al. Effi- cacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial. BMC Neurol 2008;8:33.
  • Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004;45:13- 18.

Rash associated with Pregabalin: A case report

Yıl 2013, , 107 - 109, 01.03.2013
https://doi.org/10.5799/ahinjs.01.2013.01.0244

Öz

A 48-year-old man with erythematous, maculopapular rash localized to his extremities and lumbar region that he had been receiving oral pregabalin 300 mg per day for 2 months to treat his neuropathy was applied. The Nara­njo probability scale indicates a probable relationship be­tween the development of rash and use of pregabalin by our patient. Pregabalin was discontinued and antihista­minic treatment, oral methyprednisolone and topical ste­roid cream were given to treat the rash. The rash almost completely resolved one week after pregabalin was dis­continued. Pregabalin-induced rash was rarely reported in Phase 3 clinical trials, and there is currently only one available report on the development of a rash coinciding with the use of pregabalin. No clear mechanisms reported for rash associated with pregabalin. It is usually recom­mended to start pregabalin with low doses and slow in­creases might prevent the incidence of side effects. J Clin Exp Invest 2013; 4 (1): 107-109

Kaynakça

  • Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105:1805- 1815.
  • Mula M, Pini S, Cassano GB. The role of anticonvul- sant drugs in anxiety disorders: a critical review of the evi-dence. J Clin Psychopharmacol 2007;27:263-272.
  • Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008;1:561-562.
  • Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-1709.
  • Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapen- tin, lamotrigine, and carbamazepine. Neurology 2005;64:1868-1873.
  • Smith TL, Baldwin A, Cunningham LL Jr, et al. Rash Associated with Pregabalin Use. Ann Pharmacother 2008;42:1899-1902.
  • Pushkin R, Frassetto L, Tsourounis C, et al. Improving the reporting of adverse drug reactions in the hospital set-ting. Postgrad Med 2010;122:154-164.
  • Alvestad S, Lydersen S, Brodtkorb E. Rash from anti- epileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007;48:1360-1365.
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
  • Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug- induced skin, nail and hair disorders. Drug Saf 2007;30:1011-1030.
  • Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with prega- balin: A randomized, placebo-controlled trial. J Pain 2005;6:253-260.
  • Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;63:2104- 2110.
  • Rosenstock J, Tuchman M, LaMoreaux L, et al. Pre- gabalin for the treatment of painful diabetic peripheral neuropathy: A double blind, placebo-controlled trial. Pain 2004;110:628-638.
  • Arezzo JC, Rosenstock J, Lamoreaux L, et al. Effi- cacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial. BMC Neurol 2008;8:33.
  • Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004;45:13- 18.
Toplam 15 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Olgu Sunumu
Yazarlar

Burak Uz Bu kişi benim

Ali Alkan Bu kişi benim

Hakan Göker Bu kişi benim

Nilgün Atakan Bu kişi benim

Osman İlhami Özcebe Bu kişi benim

Yayımlanma Tarihi 1 Mart 2013
Yayımlandığı Sayı Yıl 2013

Kaynak Göster

APA Uz, B., Alkan, A., Göker, H., Atakan, N., vd. (2013). Pregabalin ilişkili döküntü: Olgu sunumu. Journal of Clinical and Experimental Investigations, 4(1), 107-109. https://doi.org/10.5799/ahinjs.01.2013.01.0244
AMA Uz B, Alkan A, Göker H, Atakan N, Özcebe Oİ. Pregabalin ilişkili döküntü: Olgu sunumu. J Clin Exp Invest. Mart 2013;4(1):107-109. doi:10.5799/ahinjs.01.2013.01.0244
Chicago Uz, Burak, Ali Alkan, Hakan Göker, Nilgün Atakan, ve Osman İlhami Özcebe. “Pregabalin ilişkili döküntü: Olgu Sunumu”. Journal of Clinical and Experimental Investigations 4, sy. 1 (Mart 2013): 107-9. https://doi.org/10.5799/ahinjs.01.2013.01.0244.
EndNote Uz B, Alkan A, Göker H, Atakan N, Özcebe Oİ (01 Mart 2013) Pregabalin ilişkili döküntü: Olgu sunumu. Journal of Clinical and Experimental Investigations 4 1 107–109.
IEEE B. Uz, A. Alkan, H. Göker, N. Atakan, ve O. İ. Özcebe, “Pregabalin ilişkili döküntü: Olgu sunumu”, J Clin Exp Invest, c. 4, sy. 1, ss. 107–109, 2013, doi: 10.5799/ahinjs.01.2013.01.0244.
ISNAD Uz, Burak vd. “Pregabalin ilişkili döküntü: Olgu Sunumu”. Journal of Clinical and Experimental Investigations 4/1 (Mart 2013), 107-109. https://doi.org/10.5799/ahinjs.01.2013.01.0244.
JAMA Uz B, Alkan A, Göker H, Atakan N, Özcebe Oİ. Pregabalin ilişkili döküntü: Olgu sunumu. J Clin Exp Invest. 2013;4:107–109.
MLA Uz, Burak vd. “Pregabalin ilişkili döküntü: Olgu Sunumu”. Journal of Clinical and Experimental Investigations, c. 4, sy. 1, 2013, ss. 107-9, doi:10.5799/ahinjs.01.2013.01.0244.
Vancouver Uz B, Alkan A, Göker H, Atakan N, Özcebe Oİ. Pregabalin ilişkili döküntü: Olgu sunumu. J Clin Exp Invest. 2013;4(1):107-9.